Kymera Therapeutics
NASDAQ · KYMR·Watertown, MA·Small-cap·Phase 2
Biotech pioneering targeted protein degradation (TPD) using heterobifunctional small-molecule degraders. Lead programs in immunology (IRAK4, STAT6) with oncology programs (MDM2, STAT3) behind.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Kymera Therapeutics Corporate Presentation — February 2026 | Corporate overview | February 25, 2026 | 71 |